The transformative impact of AI-based algorithms on the health care industry offers both immense potential for improving medical outcomes and significant challenges related to bias and disparities. The unexpected discovery by radiologist Judy Gichoya, M.D., and her team that AI could predict a
Mirum Pharmaceuticals recently made headlines as they secured FDA approval for Ctexli, also known as chenodiol, as the first treatment for cerebrotendinous xanthomatosis (CTX). CTX, a rare genetic lipid storage disease, affects an estimated 3 to 5 individuals per 100,000. This approval came after a
Nanomedicine has made remarkable strides since the 1950s, revolutionizing the way drugs are delivered within the body. A recent breakthrough by scientists at ETH Zürich leverages sound waves to control microscopic flower-like zinc oxide particles for targeted drug delivery, marking a significant
Ivan Kairatov is a Biopharma expert, with deep knowledge of tech and innovation in the industry and experience in research and development. Today, we will be discussing his insights on two recently introduced health policy legislation aimed at improving telehealth access and expediting lung cancer
Ivan Kairatov is a Biopharma expert, with deep knowledge of tech and innovation in the industry and experience in research and development. Can you tell us a little about your professional background and your role as a biopharma expert? Certainly. I have spent the last couple of decades working at
In today’s healthcare landscape, data is more abundant than ever. Hospitals, research institutions, and medical professionals collect vast amounts of information—from patient histories and lab results to imaging scans and clinical trial data. However, the sheer volume and complexity of this data
